Oncology News

Stereotactic body radiation therapy followed by sorafenib extended survival compared with sorafenib alone among patients with hepatocellular carcinoma, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

Adjuvant therapy with atezolizumab and bevacizumab reduced recurrence risk compared with active surveillance for patients with certain types of early-stage liver cancer, according to topline data released by the agents’ manufacturer.

Robotic liver resection for hepatocellular carcinoma yielded better perioperative tolerability and may be a safe and effective alternative to open liver resection, according to research published in JAMA Surgery.

Perioperative complication rates were similar between simultaneous and delayed resection of liver metastasis and colorectal cancer, although survival benefits of simultaneous resection were greater in patients with KRAS wild-type tumors.

WASHINGTON — Fewer Black and Hispanic patients received curative treatment for early-stage hepatocellular carcinoma compared with white patients, according to research presented at The Liver Meeting.

WASHINGTON — The MELD score at transplant minus three points policy led to poor survival and recurrence outcomes after liver transplantation among patients with hepatocellular carcinoma, according to research at The Liver Meeting.

The FDA granted orphan drug designation to OTX-2002 for the treatment of hepatocellular carcinoma, according to the agent’s manufacturer.

The FDA approved tremelimumab in combination with durvalumab for adults with unresectable hepatocellular carcinoma.

Second- and third-generation individuals of Mexican descent who reside in the U.S. had a higher risk for developing hepatocellular carcinoma than first-generation U.S. Mexicans, according to study results.

Investigators have identified an elevated risk for hepatocellular carcinoma in people exposed to per- and polyfluoroalkyl substances, according to a study published in JHEP Reports.